COMPASS Pathways: Acquires Intellectual Property Portfolio of New Psychedelic Compounds and Prodrugs (Form 6-K)


COMPASS Pathways acquires intellectual property portfolio of novel psychedelic compounds and prodrugs

London, UK – September 14, 2021

COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced it has acquired an intellectual property portfolio (PI) comprising patent applications covering a variety of psychedelics and empathogens. The intellectual property was developed in collaboration with inventor Matthias Grill PhD, founder and CEO of MiHKAL GmbH in Basel, Switzerland, who will work with COMPASS on an exclusive research project to develop new product candidates.

Substances covered by the IP portfolio include a variety of psychedelic and empathogenic compounds, some of which are prodrugs – pharmacologically inactive compounds that are metabolized inside the body to produce an active drug. The new substances include new derivatives of known compounds, increasing confidence in therapeutic effects and safety profile while providing optimized characteristics.

Dr Matthias Grill has been involved in psychedelic chemistry research for over 15 years, earning his PhD from the Max Planck Institute. He has held R&D manager positions at Arbolea GmbH, Lipomed AG and THC Pharm GmbH, and has synthesized psychedelics for a number of human research studies, including at the University of Basel and at the National Institute of Mental Health in the Czech Republic.

Dr Grill said: “The chemistry always happens inside the vial and not on the paper. Inspired by the work of chemists like Albert Hofmann and Alexander Shulgin, I am proud to develop these evolved compounds in Switzerland, where many of the earliest psychedelics were researched and first synthesized. We are creating new candidates to tackle many of the mental health challenges we face today.

Lars Wilde, Commercial Director, President and Co-Founder of COMPASS Pathways, said: “We are delighted to be working with Matthias and MiHKAL GmbH. This agreement will strengthen and expand our intellectual property and development portfolio with new compounds. We plan to move some of these compounds into clinical development over the next two years, bringing us closer to our goal of helping patients with urgent unmet mental health care needs. ‘


About COMPASS Pathways

COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our goal is to improve the lives of those with mental health problems who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a breakthrough therapy by the United States Food and Drug Administration (FDA) for treatment-resistant depression (TRD), and we are currently conducting a Phase IIb clinical trial of psilocybin therapy for TRD, in 22 sites across Europe and North America. We are headquartered in London, UK, with offices in New York, USA. Our vision is a world of mental well-being.

Availability of other information on COMPASS Pathways

Investors and others should note that we communicate with our investors and the public using our website (, our investor relations website ( and on social media (LinkedIn ), including, but not limited to, investor presentations and investor information sheets, US Securities and Exchange Commission filings, press releases, public conference calls, and webcasts. The information that we post on these channels and websites could be considered important information. Therefore, we encourage investors, the media and others interested in us to regularly review the information posted on these channels, including the Investor Relations website.

This channel list may be updated from time to time on our Investor Relations website and may include additional social media channels. The content of our website or these channels, or any other website accessible from our website or these channels, will not be deemed to be incorporated by reference in a filing under the Securities Act of 1933.

Forward-looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. In some cases, forward-looking statements may be identified by words such as “could”, “could”, “will”, “could”, “should”, “should”, “expect”, “intention”. ‘,’ Plan ‘,’ objective ‘,’ anticipate ‘,’ believe ‘,’ contemplate ‘,’ estimate ‘,’ predict ‘,’ potential ‘,’ continue ‘and’ in progress’, or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements include express or implied statements regarding, among other things, the potential effectiveness of the compounds included in the acquired intellectual property portfolio in the treatment of mental illnesses, COMPASS’s expectations for progress and the expected timeline for progress. one or more of the included compounds. in the intellectual property portfolio acquired in preclinical studies and clinical development, the business strategy and objectives of COMPASS, the ability of COMPASS to continue to advance its research, including COMP360 and any product candidate selected from the acquired compounds, and COMPASS’s expectations regarding the benefits of its psilocybin therapy, including COMP360. The forward-looking statements contained in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements as they involve known and unknown risks, uncertainties and other factors, many of which are outside the control of COMPASS and which could cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by such forward-looking statements.

These risks, uncertainties and other factors include, among others: and the risks and uncertainties described under the heading “Risk Factors” in the COMPASS Annual Report on Form 20-F filed with the Securities and Exchange Commission (SEC) of United States on March 9, 2021 and in subsequent COMPASS filings with the SEC, which are available on the SEC’s website at Except as required by law, COMPASS disclaims any intention or responsibility to update or revise any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on COMPASS’s current expectations and speak only as of the date hereof.


Media: Tracy Cheung, [email protected], +44 7966 309024
Investors: Stephen Schultz, [email protected], +1 401 290 7423


Compass Pathways plc published this content on September 15, 2021 and is solely responsible for the information it contains. Distributed by Public, unedited and unmodified, on September 15, 2021 09:21:10 PM UTC.


About Author

Leave A Reply